Highlights•Platinum-resistant diseases are related to worst prognosis in ovarian
cancers.•Neoadjuvant chemotherapy may be related to platinum resistance clinically.•Why …

OBJECTIVE: Primary debulking surgery (PDS) has historically been the standard treatment
for advanced ovarian cancer. Recent data appear to support a paradigm shift toward …

It remains controversial whether neoadjuvant chemotherapy (NACT) followed by interval
debulking surgery (IDS) induces chemoresistance in advanced epithelial ovarian cancer …

Abstract Objective TP53 K351N mutation is associated with acquired cisplatin resistance in
ovarian cancer cells following exposure to cisplatin. We investigated the effect of TP53 …

Primary debulking surgery (PDS) followed by platinum-based chemotherapy has been the
cornerstone of treatment for advanced ovarian cancer for decades. Primary debulking …

Background Interval debulking surgery (IDS) is an option for treating patients with advanced
ovarian carcinoma. Two randomized trials have shown similar survival rates for primary …

The current management of advanced ovarian cancer consists of aggressive primary
cytoreductive surgery (PCS) followed by combination platinum based chemotherapy. Recent …

Objective To compare the effectiveness and safety of neoadjuvant chemotherapy with
carboplatin/paclitaxel followed by interval debulking surgery (NACT-IDS) to primary …

Ovarian cancer remains the leading cause of death from gynecological cancer. Survival is
significantly related to the stage of the disease at diagnosis. Of quite importance is primary …

Abstract Background/Aim: This study aimed to compare neoadjuvant chemotherapy (NAC)
followed by interval debulking surgery (IDS) with primary debulking surgery (PDS) followed …